CL2011002566A1 - Un metodo para identificar una sustancia que media la sobrerregulacion transcripcional de un gen biomarcador o detectar si una sustancia media la sobrerregulacion transcripcional de un gen biomarcador. - Google Patents

Un metodo para identificar una sustancia que media la sobrerregulacion transcripcional de un gen biomarcador o detectar si una sustancia media la sobrerregulacion transcripcional de un gen biomarcador.

Info

Publication number
CL2011002566A1
CL2011002566A1 CL2011002566A CL2011002566A CL2011002566A1 CL 2011002566 A1 CL2011002566 A1 CL 2011002566A1 CL 2011002566 A CL2011002566 A CL 2011002566A CL 2011002566 A CL2011002566 A CL 2011002566A CL 2011002566 A1 CL2011002566 A1 CL 2011002566A1
Authority
CL
Chile
Prior art keywords
substance
overregulation
transcriptional
mediates
biomarker gene
Prior art date
Application number
CL2011002566A
Other languages
English (en)
Inventor
Jose A Aktas Huseyin Halperin
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002566(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard College filed Critical Harvard College
Publication of CL2011002566A1 publication Critical patent/CL2011002566A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN BIOENSAYOS PARA DETECTAR LA CAPACIDAD DE UNA MUESTRA DE UNA SUSTANCIA ALIMENTICIA, SUPLEMENTO NUTRITIVO, AGENTE TERAPÉUTICO Y/O AGENTE QUE PREVIENE UNA ENFERMEDAD, CON RELACIÓN A AQUÉLLA DE UNA SEGUNDA MUESTRA DE TAL SUSTANCIA, SUPLEMENTO Y/O AGENTE PARA INHIBIR, SOBRERREGULAR O MODULAR DE OTRA MANERA EL INICIO DE LA TRADUCCIÓN, Y DEMOSTRAR POR LO TANTO UN EFECTO CURATIVO Y/O PREVENTIVO DE UNA ENFERMEDAD EN UN HUMANO Y/O ANIMAL QUE CONSUME TAL SUSTANCIA, SUPLEMENTO Y/O AGENTE O A CUANDO SE LE ADMINISTRA TAL SUSTANCIA, SUPLEMENTO Y/O AGENTE.
CL2011002566A 2009-04-17 2011-10-14 Un metodo para identificar una sustancia que media la sobrerregulacion transcripcional de un gen biomarcador o detectar si una sustancia media la sobrerregulacion transcripcional de un gen biomarcador. CL2011002566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17033009P 2009-04-17 2009-04-17

Publications (1)

Publication Number Publication Date
CL2011002566A1 true CL2011002566A1 (es) 2012-03-23

Family

ID=42983164

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002566A CL2011002566A1 (es) 2009-04-17 2011-10-14 Un metodo para identificar una sustancia que media la sobrerregulacion transcripcional de un gen biomarcador o detectar si una sustancia media la sobrerregulacion transcripcional de un gen biomarcador.

Country Status (20)

Country Link
US (2) US8999646B2 (es)
EP (1) EP2419541B1 (es)
JP (2) JP2012523837A (es)
KR (2) KR101674626B1 (es)
CN (2) CN102459637B (es)
AU (1) AU2010236247B2 (es)
BR (1) BRPI1006624B1 (es)
CA (1) CA2758546C (es)
CL (1) CL2011002566A1 (es)
CO (1) CO6460755A2 (es)
DK (1) DK2419541T3 (es)
ES (1) ES2629425T3 (es)
HU (1) HUE033579T2 (es)
MA (1) MA33324B1 (es)
MX (1) MX337517B (es)
PE (2) PE20120793A1 (es)
PL (1) PL2419541T3 (es)
PT (1) PT2419541T (es)
RU (2) RU2570626C2 (es)
WO (1) WO2010121131A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9952200B2 (en) * 2012-07-20 2018-04-24 President And Fellows Of Harvard College Cell based quality control bioassays for nutriceutical and medicinal products
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CN112986589B (zh) 2017-01-05 2023-01-24 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
CN111378707B (zh) * 2018-12-28 2022-06-21 康码（上海）生物科技有限公司 一种体外无细胞蛋白合成体系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2041256C1 (ru) * 1993-09-17 1995-08-09 Акционерное общество закрытого типа "Эри Марин" Способ переработки рыбьего жира с получением концентрата этиловых эфиров полиненасыщенных жирных кислот
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
US20020018989A1 (en) * 1996-11-07 2002-02-14 Albert Beaufour Method of identifying pharmaceuticals from plant extracts
BR0008122A (pt) 1999-02-10 2001-11-13 Oxford Natural Products Plc Processos para estabelecer uma especificaçãopadrão para um material de planta medicinal, parafornecer uma amostra de um material de plantamedicinal, e para fornecer uma especificaçãopadrão para um material de planta medicinal
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
GB0205186D0 (en) * 2002-03-06 2002-04-17 Molecularnature Ltd Method for monitoring the quality of a herbal medicine
WO2008008333A2 (en) * 2006-07-11 2008-01-17 President And Fellows Of Harvard College Bioassays for quality control of nutriceuticals that inhibit, upregulate or otherwise modulate translation initiation
US9421211B2 (en) 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation

Also Published As

Publication number Publication date
PT2419541T (pt) 2017-06-14
BRPI1006624A2 (pt) 2016-04-19
MX337517B (es) 2016-03-09
CA2758546A1 (en) 2010-10-21
ES2629425T3 (es) 2017-08-09
KR101674626B1 (ko) 2016-11-09
EP2419541A2 (en) 2012-02-22
HUE033579T2 (hu) 2017-12-28
RU2642292C1 (ru) 2018-01-24
US20120135412A1 (en) 2012-05-31
US8999646B2 (en) 2015-04-07
EP2419541A4 (en) 2012-10-10
AU2010236247B2 (en) 2015-02-26
AU2010236247A1 (en) 2011-11-10
PL2419541T3 (pl) 2017-09-29
JP6185965B2 (ja) 2017-08-23
RU2570626C2 (ru) 2015-12-10
WO2010121131A2 (en) 2010-10-21
MA33324B1 (fr) 2012-06-01
CN105969847A (zh) 2016-09-28
PE20120793A1 (es) 2012-07-04
WO2010121131A3 (en) 2011-03-10
US9410946B2 (en) 2016-08-09
CA2758546C (en) 2019-02-26
EP2419541B1 (en) 2017-03-29
JP2015213521A (ja) 2015-12-03
DK2419541T3 (da) 2017-06-19
JP2012523837A (ja) 2012-10-11
PE20160883A1 (es) 2016-08-25
CN102459637B (zh) 2016-06-08
CN102459637A (zh) 2012-05-16
CO6460755A2 (es) 2012-06-15
KR20160129921A (ko) 2016-11-09
KR101769569B1 (ko) 2017-08-21
BRPI1006624B1 (pt) 2020-09-15
CN105969847B (zh) 2021-08-27
KR20120024614A (ko) 2012-03-14
MX2011010966A (es) 2011-11-02
RU2011141197A (ru) 2013-05-27
US20150185212A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
CL2011000891A1 (es) Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
EP2265724A4 (en) Direct chemical modification of microbial biomass and microbial oils
BRPI1010836A2 (pt) nutrição medicinal especializada para pacientes cirúrgicos e de trauma contendo probióticos
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
HUE041510T2 (hu) Biológiai sejtek és szövetek krioprezervációja
IT1397439B1 (it) Procedimento e dispositivi per la distribuzione di contenuti mediali e relativo prodotto informatico
BR112013015593A2 (pt) extrato de polpa e/ou de casca de abacate rica em polifenóis e composições cosméticas, dermatológicas e nutracêuticas que o compreendem.
GB0823016D0 (en) Method of fetal and maternal ECG identification across multiple epochs
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
BRPI0818741A2 (pt) equipamento e método de avaliação da presença de microorganismos no sangue
WO2011022371A3 (en) Gel product
ATE447329T1 (de) Nahrungsmittel mit bakterien und sorbitan- fettsäure
BR112013015634A2 (pt) pastilha nutricional aprimorada
BRPI1008210A2 (pt) "emulsão óleo-em-água e produto alimentício que compreende uma emulsão óleo-em-água"
GB0818613D0 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
DOP2006000208A (es) Suplementos nutricionales con fitosterol
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
BRPI0821892A2 (pt) Composição nutricional contendo dha (ácido docosa-hexaenoico), ácido rumêncio e gangliosídeos
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors
MX337517B (es) Bioensayos de control de calidad para productos nutriceuticos y medicinales.
WO2012077936A3 (en) Fluorescence-sensing probe, and fluorescence detection method, sentinel lymph node dissection method and target-guided surgery method which use the probe
GB0816367D0 (en) Methods of treatment of medium and/or liquid and/or solid foodstuff and ultrasonic processor